Latest public offering nets $522mm for bluebird bio

15:40 EDT 25 Jul 2018 | Elsevier Business Intelligence

Immunotherapy and gene editing firm bluebird bio Inc. netted $522mm through the public offering of 3.4mm common shares at $16...

Original Article: Latest public offering nets $522mm for bluebird bio


More From BioPortfolio on "Latest public offering nets $522mm for bluebird bio"

Quick Search


Relevant Topics

Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...